Adverse event consortium begins second phase

The International Serious Adverse Events Consortium (SAEC) began the second phase of ongoing research to identify genetic markers that could predict which patients are at risk of rare drug-related adverse events. Goals for the second phase include completing two genomewide genotyping studies focused on co-amoxiclav liver injury and clozapine agranulocytosis to investigate the role of low frequency variants in serious adverse event risk; and establishing an acute hypersensitivity reaction research network. Last year, the consortium published data from the study's first phase that showed patients carrying the HLA-B 5701 allele were more likely than non-carriers to develop flucloxacillin-induced liver injury. ...